Cargando…

Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers

Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet majo...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Soo-Youl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354324/
https://www.ncbi.nlm.nih.gov/pubmed/25767677
http://dx.doi.org/10.4062/biomolther.2015.013